Operating Advisor US Healthcare John Johnson



Operating area



John is a recognized leader in the pharmaceutical and biotechnology industry with more than three decades of experience. John has held executive management roles at leading global corporations, including Melinta Therapeutics (CEO), Johnson & Johnson (Group Chairman of Pharmaceuticals), Eli Lilly & Company (President of Oncology Unit), ImClone (CEO) and Pfizer, Inc. He holds degrees from the University of Rochester's Simon Business School, East Stroudsburg University of Pennsylvania and the University of Pittsburg. Formerly a Director on the Board of BioAgilytix through his advisor role with Cobepa, John is currently the CEO of Cobepa’s portfolio company, Reaction Biology, which was acquired in March 2022.

Member of